Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis
Abstract
Background: Peripheral muscle dysfunction is a well-established extrapulmonary manifestation of cystic fibrosis (CF), contributing to exercise intolerance and reduced quality of life. However, its persistence in the era of highly effective CFTR modulator therapy (HEMT) remains unclear. Methods: Fifty-six people with CF (age: 31 ± 13 years, BMI: 22 [20-24] kg⋅m -2 ; FEV 1 %: 77 ± 24; 95% treated with elexacaftor/tezacaftor/ivacaftor for 31 ± 11 months) were compared with 46 healthy controls of comparable age and sex distribution. Muscle function was assessed following international recommendations, including quadriceps strength (primary outcome), endurance and thickness, handgrip strength, and squat jump performance. Physical activity was assessed using accelerometry. Results: Compared with controls, people with CF exhibited lower quadriceps strength (203 [161-304] vs. 284 [238-335] N⋅m, p = 0.001, rrb = 0.35) and endurance (p < 0.001, rrb = 0.47). Quadriceps thickness (p = 0.002, rrb = 0.34) and handgrip strength (p = 0.009, d = 0.48) were also lower. After normalisation to muscle thickness, quadriceps strength remained lower (p = 0.01, rrb = 0.27), whereas habitual physical activity levels did not differ significantly between groups. Conclusion: This is the first large controlled study to comprehensively assess peripheral muscle function in people with CF following long-term HEMT exposure. Despite this prolonged exposure, clinically relevant impairments remained evident across multiple dimensions of muscle function. Altered muscle performance cannot be explained solely by muscle deconditioning and lower muscle size, suggesting intrinsic muscle alterations. These findings support the need for comprehensive assessment of peripheral muscle function and the continued prioritisation of interventions aiming to optimise muscle health.
Related
- CFTR dysfunction in the intestinal epithelium is sufficient to promote pathogenic expansion of E. coli and enhanced barrier permeability in cystic fibrosis
- OPA1 controls mitochondrial dysfunction-driven liver fibrosis in MASLD
- Taxonomic Bias Persists in Ecology and Evolution Research Despite Decades of Concern
- Multisensory perceptual decision-making persists as alertness fades, even in the absence of an overt response
- Individual leadership in cattle persists when collective movement is induced by robotic herding
BibTeX
@article{bronstein2026peripheral,
title = {{Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis}},
author = {Antoine Bronstein and Elise Zitta and Oussama Saidi and Nadège Goriot-Raynaud and Laurent Mely and Mathieu Gruet},
journal = {Journal of Cystic Fibrosis},
year = {2026},
month = oct,
doi = {10.1016/j.jcf.2026.08.008},
url = {https://univ-tln.hal.science/hal-05794114v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peripheral muscle dysfunction persists in the era of highly effective CFTR modulators in cystic fibrosis
AU - Antoine Bronstein
AU - Elise Zitta
AU - Oussama Saidi
AU - Nadège Goriot-Raynaud
AU - Laurent Mely
AU - Mathieu Gruet
PY - 2026
DA - 2026/10/12
JO - Journal of Cystic Fibrosis
DO - 10.1016/j.jcf.2026.08.008
UR - https://univ-tln.hal.science/hal-05794114v1
AB - Background: Peripheral muscle dysfunction is a well-established extrapulmonary manifestation of cystic fibrosis (CF), contributing to exercise intolerance and reduced quality of life. However, its persistence in the era of highly effective CFTR modulator therapy (HEMT) remains unclear. Methods: Fifty-six people with CF (age: 31 ± 13 years, BMI: 22 [20-24] kg⋅m -2 ; FEV 1 %: 77 ± 24; 95% treated with elexacaftor/tezacaftor/ivacaftor for 31 ± 11 months) were compared with 46 healthy controls of comparable age and sex distribution. Muscle function was assessed following international recommendations, including quadriceps strength (primary outcome), endurance and thickness, handgrip strength, and squat jump performance. Physical activity was assessed using accelerometry. Results: Compared with controls, people with CF exhibited lower quadriceps strength (203 [161-304] vs. 284 [238-335] N⋅m, p = 0.001, rrb = 0.35) and endurance (p < 0.001, rrb = 0.47). Quadriceps thickness (p = 0.002, rrb = 0.34) and handgrip strength (p = 0.009, d = 0.48) were also lower. After normalisation to muscle thickness, quadriceps strength remained lower (p = 0.01, rrb = 0.27), whereas habitual physical activity levels did not differ significantly between groups. Conclusion: This is the first large controlled study to comprehensively assess peripheral muscle function in people with CF following long-term HEMT exposure. Despite this prolonged exposure, clinically relevant impairments remained evident across multiple dimensions of muscle function. Altered muscle performance cannot be explained solely by muscle deconditioning and lower muscle size, suggesting intrinsic muscle alterations. These findings support the need for comprehensive assessment of peripheral muscle function and the continued prioritisation of interventions aiming to optimise muscle health.
SN - 1569-1993
SN - 1873-5010
ER -